Key facts: IFF Beats Q3; Raises Outlook, Completes Buyback

What happened

IFF reported third-quarter 2026 sales of $1.942 billion, up 4% year over year, and adjusted EBITDA, a measure of operating earnings, of $403 million, up 5%. It beat sales and adjusted earnings-per-share expectations, raised its 2026 outlook, completed a $500 million share buyback, and kept its Food Ingredients separation on schedule for completion by the end of Q2 2027.

Confirmed

Global impact / market context

Higher sales and operating earnings, along with a raised annual outlook, point to stronger near-term business performance. However, the company flagged lower fourth-quarter profitability as costs rise and it reinvests in Health & Biosciences, which could limit how much of its sales growth reaches earnings.

Analyst inference

The completed $500 million buyback returns cash to shareholders and reduces the number of shares outstanding, while the planned Food Ingredients separation could reshape IFF’s business mix after closing. Its timing and the fourth-quarter profit warning create different signals for investors assessing growth and earnings quality.

Analyst inference

What to watch

1. Watch whether IFF’s next results show continued volume growth across Taste, Scent, and Health & Biosciences, since broad demand helped drive third-quarter sales. Analyst inference
2. Track the expected Food Ingredients sale and separation through the planned Q2 2027 completion; a delay could postpone the intended change in business structure. Confirmed
3. Compare fourth-quarter profit with the company’s warning about higher costs and Health & Biosciences reinvestment to judge how strongly these pressures affect earnings. Analyst inference

Evidence

• Original source link unavailable